The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study

Basit Öğe Kaydı
dc.contributor.authorSahin, S.
dc.contributor.authorKaratas, F.
dc.date.accessioned2024-09-29T16:22:32Z
dc.date.available2024-09-29T16:22:32Z
dc.date.issued2019
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPurpose: To investigate the effects of sidedness on survival and treatment outcomes in patients with metastatic colorectal cancer (mCRC), since the accumulated data have increasingly reported that patient with right-sided mCRC are found to be associated with worse overall survival (OS) and poor response to anti-epidermal growth factor receptor (anti-EGFR) agents. Methods: This was a multi-center retrospective analysis of 177 patients with mCRC, who were treated and followed between 2014 and 2018 in different parts of Turkey. Patients were divided into 2 groups according to the primary tumor localization as right or left colon cancer. Clinical and demographic characteristics, treatment outcomes, and survival were analyzed to determine whether there was any association with tumor localization. Results: There were 53 (30%) patients with mCRC in the right group and 124 (70%) in the left group, with no difference between the groups in terms of clinical and demographic characteristics. There was no difference in OS between the left and right side localization in any RAS-mutant mCRC patients (22.1 vs. 27.9 months, respectively, p=0.19), whereas patients with all RAS-wild type tumor in the right colon were associated with a worse OS than left-sided counterparts (19.4 vs 29.9 months, respectively, p=0.01). Multivariate analysis revealed that the right-sided tumor (HR, 1.74; 95% CI: 1.165-2.608; p=0.007), the presence of comorbid disease (HR, 1.58; 95% CI: 1.079-2.321, p=0.019), body mass index (BMI) <25 (HR, 1.61; 95% CI: 1.108-2.352, p=0.013), grade III tumor (HR, 1.65; 95% CI: 1.109-2.457, p=0.014), and being unable to metastasectomy (HR, 2.10; 95% CI: 1.235-3582, p=0.006) were found to be independent predictors of worse survival. Conclusion: While right side localization was an independent negative predictor of survival in patients with mCRC, tumor sidedness was not found to be associated with response to treatment. The worse OS in right localization may be due to the aggressive nature of right-sided colon tumors which show faster progression, since their response to treatment does not appear to be different. © 2019 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage487en_US
dc.identifier.issn1107-0625
dc.identifier.issue2en_US
dc.identifier.pmid31127994en_US
dc.identifier.scopus2-s2.0-85064913993en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage479en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/10134
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-EGFR therapyen_US
dc.subjectAnti-VEGF therapyen_US
dc.subjectMetastatic colorectal canceren_US
dc.subjectPrognosisen_US
dc.subjectSidednessen_US
dc.subjectSurvivalen_US
dc.titleThe impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu